Pfizer Q3 2026 slides: 32% growth in new products, guidance raised
Pfizer (PFE) reported Q3 2026 revenue of $16.6B, beating expectations, and raised full-year guidance to $62.0-$64.0B. New products grew 32%, offsetting declines in COVID-related sales. R&D expenses rose 18% due to investments in oncology and obesity. The stock slipped 0.72% premarket.
How this was made
The 30-second read
Why it matters
Raised 2026 revenue and EPS guidance is the primary decision input for traders, with additional support from non-COVID operational growth and specific clinical progress updates (including ELREXFIO trial data) that may improve perceived pipeline value.
Market read
Traders can update positioning based on the raised 2026 guidance ranges and the market’s apparent focus on longer-term patent-expiration and pricing risks.
What to watch
No share repurchases planned for 2026, and R&D acceleration could pressure margins or raise execution risk if pipeline milestones slip.
Background
Pfizer’s Q3 2026 print is framed as a transition quarter as pandemic-related revenues normalize, while management leans on launched and acquired products and pipeline execution.
Ticker impact
Pfizer raised full-year 2026 revenue guidance to $62.0-$64.0B and adjusted EPS to $2.95-$3.05 after Q3 results beat expectations.
Likely near-term support as the market reprices the raised guidance, tempered by concerns about future exclusivity losses.
The article reports a fresh guidance raise with specific revenue and EPS ranges, plus operational growth in non-COVID products and launched/acquired revenue acceleration.
Market effects
Signals resilience in large pharma transition away from COVID-era revenue, with investors focusing on pipeline and post-exclusivity mitigation.
Primarily US large-cap pharma sentiment; could influence broader healthcare earnings expectations.
Guidance and pipeline progress may affect global pharma peers’ read-through on demand durability and GLP-1/oncology competitive positioning.
Counterpoint
The stock’s premarket slip despite guidance raises suggests investors may be discounting the durability of launched-and-acquired growth versus the magnitude/timing of upcoming exclusivity losses.
Key entities
- companyPfizer Inc.
US-listed pharma company reporting Q3 2026 results and raising full-year 2026 guidance, alongside pipeline and AI platform updates.
- drugELREXFIO (elranatamab-bcmm)
Pfizer multiple myeloma therapy discussed with Phase 3 progression-free survival and safety outcomes, plus planned regulatory submissions.
- drugberobenatide
Pfizer ultra-long-acting GLP-1 receptor agonist referenced as progressing through pivotal studies.
